Paclitaxel-loaded Pluronic nanoparticles formed by a temperature-induced phase transition for cancer therapy

Keun Sang Oh, Ji Yung Song, Sun Hang Cho, Bum Suk Lee, Sang Yoon Kim, Kwang Meyung Kim, Hyesung Jeon, Ick Chan Kwon, Soon Hong Yuk

Research output: Contribution to journalArticle

64 Citations (Scopus)

Abstract

We prepared nanoparticles by a temperature-induced phase transition in a mixture of Pluronic F-68 and liquid PEG (polyethylene glycol, molecular weight: 400) containing paclitaxel (PTX) with a fast, simple, continuous and solvent-free process. The liquid PEG is used as solubilizer of PTX and the polymer for the encapsulation of PTX is composed of Pluronic F-68. At the phase transition temperature, the polymer mixture was changed to the liquid phase, and stirring the liquid polymer mixture formed emulsions composed of PEG containing PTX and liquidized Pluronic F-68. On the nanometer scale, PEG containing PTX was encapsulated by Pluronic F-68 by cooling to 0 °C to form Pluronic nanoparticles. The morphology and size distribution of the prepared Pluronic nanoparticles were observed using FE-SEM and TEM, and a particle size analyzer and cryo-TEM were used to observe the shape of paclitaxel-loaded Pluronic nanoparticles in an aqueous state. To apply Pluronic nanoparticles as a delivery system for cancer therapy, the release pattern of PTX, a model anti-cancer drug, was observed and the tumor growth was monitored by injecting the PTX-loaded Pluronic nanoparticles into the tail veins of tumor-bearing mice. We also evaluated the time-dependent excretion profile, in vivo biodistribution, circulation time, and tumor targeting ability of PTX-loaded Pluronic nanoparticles using non-invasive live animal imaging technology. In the early stage within 7 h of release, the loaded PTX was rapidly released and the sustained release was observed for up to 48 h. In vivo studies, PTX-loaded Pluronic nanoparticles were observed with higher anti-tumor efficacy compared with PTX formulated in Cremophor EL.

Original languageEnglish
Pages (from-to)344-350
Number of pages7
JournalJournal of Controlled Release
Volume148
Issue number3
DOIs
Publication statusPublished - 2010 Dec 20
Externally publishedYes

Fingerprint

Poloxamer
Phase Transition
Paclitaxel
Nanoparticles
Temperature
Neoplasms
Therapeutics
Polymers
Transition Temperature
Emulsions
Particle Size
Tail
Veins

Keywords

  • Anti-tumor efficacy
  • Cancer therapy
  • Non-invasive animal imaging
  • Pluronic nanoparticles
  • Temperature-induced phase transition

ASJC Scopus subject areas

  • Pharmaceutical Science

Cite this

Paclitaxel-loaded Pluronic nanoparticles formed by a temperature-induced phase transition for cancer therapy. / Oh, Keun Sang; Song, Ji Yung; Cho, Sun Hang; Lee, Bum Suk; Kim, Sang Yoon; Kim, Kwang Meyung; Jeon, Hyesung; Kwon, Ick Chan; Yuk, Soon Hong.

In: Journal of Controlled Release, Vol. 148, No. 3, 20.12.2010, p. 344-350.

Research output: Contribution to journalArticle

Oh, Keun Sang ; Song, Ji Yung ; Cho, Sun Hang ; Lee, Bum Suk ; Kim, Sang Yoon ; Kim, Kwang Meyung ; Jeon, Hyesung ; Kwon, Ick Chan ; Yuk, Soon Hong. / Paclitaxel-loaded Pluronic nanoparticles formed by a temperature-induced phase transition for cancer therapy. In: Journal of Controlled Release. 2010 ; Vol. 148, No. 3. pp. 344-350.
@article{e0122fe70c764760a6ba0bfd5943cd69,
title = "Paclitaxel-loaded Pluronic nanoparticles formed by a temperature-induced phase transition for cancer therapy",
abstract = "We prepared nanoparticles by a temperature-induced phase transition in a mixture of Pluronic F-68 and liquid PEG (polyethylene glycol, molecular weight: 400) containing paclitaxel (PTX) with a fast, simple, continuous and solvent-free process. The liquid PEG is used as solubilizer of PTX and the polymer for the encapsulation of PTX is composed of Pluronic F-68. At the phase transition temperature, the polymer mixture was changed to the liquid phase, and stirring the liquid polymer mixture formed emulsions composed of PEG containing PTX and liquidized Pluronic F-68. On the nanometer scale, PEG containing PTX was encapsulated by Pluronic F-68 by cooling to 0 °C to form Pluronic nanoparticles. The morphology and size distribution of the prepared Pluronic nanoparticles were observed using FE-SEM and TEM, and a particle size analyzer and cryo-TEM were used to observe the shape of paclitaxel-loaded Pluronic nanoparticles in an aqueous state. To apply Pluronic nanoparticles as a delivery system for cancer therapy, the release pattern of PTX, a model anti-cancer drug, was observed and the tumor growth was monitored by injecting the PTX-loaded Pluronic nanoparticles into the tail veins of tumor-bearing mice. We also evaluated the time-dependent excretion profile, in vivo biodistribution, circulation time, and tumor targeting ability of PTX-loaded Pluronic nanoparticles using non-invasive live animal imaging technology. In the early stage within 7 h of release, the loaded PTX was rapidly released and the sustained release was observed for up to 48 h. In vivo studies, PTX-loaded Pluronic nanoparticles were observed with higher anti-tumor efficacy compared with PTX formulated in Cremophor EL.",
keywords = "Anti-tumor efficacy, Cancer therapy, Non-invasive animal imaging, Pluronic nanoparticles, Temperature-induced phase transition",
author = "Oh, {Keun Sang} and Song, {Ji Yung} and Cho, {Sun Hang} and Lee, {Bum Suk} and Kim, {Sang Yoon} and Kim, {Kwang Meyung} and Hyesung Jeon and Kwon, {Ick Chan} and Yuk, {Soon Hong}",
year = "2010",
month = "12",
day = "20",
doi = "10.1016/j.jconrel.2010.08.021",
language = "English",
volume = "148",
pages = "344--350",
journal = "Journal of Controlled Release",
issn = "0168-3659",
publisher = "Elsevier",
number = "3",

}

TY - JOUR

T1 - Paclitaxel-loaded Pluronic nanoparticles formed by a temperature-induced phase transition for cancer therapy

AU - Oh, Keun Sang

AU - Song, Ji Yung

AU - Cho, Sun Hang

AU - Lee, Bum Suk

AU - Kim, Sang Yoon

AU - Kim, Kwang Meyung

AU - Jeon, Hyesung

AU - Kwon, Ick Chan

AU - Yuk, Soon Hong

PY - 2010/12/20

Y1 - 2010/12/20

N2 - We prepared nanoparticles by a temperature-induced phase transition in a mixture of Pluronic F-68 and liquid PEG (polyethylene glycol, molecular weight: 400) containing paclitaxel (PTX) with a fast, simple, continuous and solvent-free process. The liquid PEG is used as solubilizer of PTX and the polymer for the encapsulation of PTX is composed of Pluronic F-68. At the phase transition temperature, the polymer mixture was changed to the liquid phase, and stirring the liquid polymer mixture formed emulsions composed of PEG containing PTX and liquidized Pluronic F-68. On the nanometer scale, PEG containing PTX was encapsulated by Pluronic F-68 by cooling to 0 °C to form Pluronic nanoparticles. The morphology and size distribution of the prepared Pluronic nanoparticles were observed using FE-SEM and TEM, and a particle size analyzer and cryo-TEM were used to observe the shape of paclitaxel-loaded Pluronic nanoparticles in an aqueous state. To apply Pluronic nanoparticles as a delivery system for cancer therapy, the release pattern of PTX, a model anti-cancer drug, was observed and the tumor growth was monitored by injecting the PTX-loaded Pluronic nanoparticles into the tail veins of tumor-bearing mice. We also evaluated the time-dependent excretion profile, in vivo biodistribution, circulation time, and tumor targeting ability of PTX-loaded Pluronic nanoparticles using non-invasive live animal imaging technology. In the early stage within 7 h of release, the loaded PTX was rapidly released and the sustained release was observed for up to 48 h. In vivo studies, PTX-loaded Pluronic nanoparticles were observed with higher anti-tumor efficacy compared with PTX formulated in Cremophor EL.

AB - We prepared nanoparticles by a temperature-induced phase transition in a mixture of Pluronic F-68 and liquid PEG (polyethylene glycol, molecular weight: 400) containing paclitaxel (PTX) with a fast, simple, continuous and solvent-free process. The liquid PEG is used as solubilizer of PTX and the polymer for the encapsulation of PTX is composed of Pluronic F-68. At the phase transition temperature, the polymer mixture was changed to the liquid phase, and stirring the liquid polymer mixture formed emulsions composed of PEG containing PTX and liquidized Pluronic F-68. On the nanometer scale, PEG containing PTX was encapsulated by Pluronic F-68 by cooling to 0 °C to form Pluronic nanoparticles. The morphology and size distribution of the prepared Pluronic nanoparticles were observed using FE-SEM and TEM, and a particle size analyzer and cryo-TEM were used to observe the shape of paclitaxel-loaded Pluronic nanoparticles in an aqueous state. To apply Pluronic nanoparticles as a delivery system for cancer therapy, the release pattern of PTX, a model anti-cancer drug, was observed and the tumor growth was monitored by injecting the PTX-loaded Pluronic nanoparticles into the tail veins of tumor-bearing mice. We also evaluated the time-dependent excretion profile, in vivo biodistribution, circulation time, and tumor targeting ability of PTX-loaded Pluronic nanoparticles using non-invasive live animal imaging technology. In the early stage within 7 h of release, the loaded PTX was rapidly released and the sustained release was observed for up to 48 h. In vivo studies, PTX-loaded Pluronic nanoparticles were observed with higher anti-tumor efficacy compared with PTX formulated in Cremophor EL.

KW - Anti-tumor efficacy

KW - Cancer therapy

KW - Non-invasive animal imaging

KW - Pluronic nanoparticles

KW - Temperature-induced phase transition

UR - http://www.scopus.com/inward/record.url?scp=78649775109&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=78649775109&partnerID=8YFLogxK

U2 - 10.1016/j.jconrel.2010.08.021

DO - 10.1016/j.jconrel.2010.08.021

M3 - Article

C2 - 20797418

AN - SCOPUS:78649775109

VL - 148

SP - 344

EP - 350

JO - Journal of Controlled Release

JF - Journal of Controlled Release

SN - 0168-3659

IS - 3

ER -